ERBB2 and intrahepatic cholangiocarcinoma: Moreover, a comparison of the immune status between HER2 amplified and non-amplified samples was performed, aiming to explore the potential utility of immunotherapy in the treatment of intrahepatic cholangiocarcinoma (ICC).